Drug Trial Radar · NCT04910568
A Study Evaluating the Safety, Pharmacokinetics, and Activity of Cevostamab in Participants With Relapsed or Refractory Multiple Myeloma
Last checked: Nov 19, 2026Latest source record: Nov 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
186
Planned (sponsor's estimate)
Start
Jul 26, 2021
Primary completion
Dec 21, 2028
Study completion Dec 21, 2028
Sponsor
- Lead sponsor
- Genentech, Inc.Roche (Genentech) (RHHBY)
- Sponsor type
- Industry
- Collaborators
- Hoffmann-La Roche
- First posted
- Jun 2, 2021
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This Phase Ib, multicenter, open-label study will evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of cevostamab monotherapy, cevostamab plus pomalidomide and dexamethasone (Pd) or cevostamab plus daratumumab and dexamethasone (Dd) which will be administered to participants with relapsed or refractory multiple myeloma (R/R MM) via intravenous (IV) infusion.
Conditions
- Multiple Myeloma
Interventions
CevostamabDrug
Cevostamab will be administered intravenously on a 28-day cycle, up to a total of 13 cycles (Arm A), in 28-day cycles Q2W followed by Q4W (Arm B) and in 21 day cycles from C1-C8 Q3W and 28-day cycles from C9 onwards Q4W (Arm C). For Arm A, participants have the option to enter re-treatment within 12 months of the end of treatment visit. For Arms B and C, participants can be treated until disease progression or unacceptable toxicity.
TocilizumabDrug
Tocilizumab will be administered for the treatment of cytokine release syndrome (CRS) when necessary.
PomalidomideDrug
Pomalidomide will be administered orally (PO) on a 28-day cycle.
DaratumumabDrug
Daratumumab will be administered subcutaneously (SC) on 21 day (C1-8) and 28-day cycles (C9 onwards).
DexamethasoneDrug
Arm A: Dexamethasone will be administered as a premedication. Arms B and C: Dexamethasone will be administered via IV or orally at 20 mg as study investigational medicinal product.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Recommended Phase II Dose (RP2D)Time frame: Baseline up to approximately 4 years
- Percentage of Participants with Adverse EventsTime frame: Baseline up to approximately 4 years
- Percentage of Dose InterruptionsTime frame: Baseline up to approximately 4 years
- Percentage of Dose ReductionsTime frame: Baseline up to approximately 4 years
- Percentage of Dose IntensityTime frame: Baseline up to approximately 4 years
- Percentage of Treatment DiscontinuationTime frame: Baseline up to approximately 4 years
Locations
34 sites in 13 countries. Site status is shown where the registry gives one.
City of Hope
Duarte, California · Recruiting
City of Hope - Lennar Foundation Cancer Center
Irvine, California · Recruiting
Colorado Blood Cancer Institute (CBCI) at Presbyterian/ St. Luke's Medical Center
Denver, Colorado · Recruiting
Winship Cancer Institute
Atlanta, Georgia · Withdrawn
Karmanos Cancer Institute.
Detroit, Michigan · Completed
Washington University School of Medicine
St Louis, Missouri · Recruiting
Peter MacCallum Cancer Centre
Melbourne, Victoria, Australia · Active not recruiting
The Alfred Hospital
Melbourne, Victoria, Australia · Recruiting
Cross Cancer Institute
Edmonton, Alberta, Canada · Active not recruiting
Hamilton Health Sciences
Hamilton, Ontario, Canada · Active not recruiting
University Health Network
Toronto, Ontario, Canada · Active not recruiting
Fakultni Nemocnice Ostrava
Ostrava, Czechia · Active not recruiting
I Interni klinika
Prague, Czechia · Withdrawn
Rigshospitalet
København Ø, Denmark · Active not recruiting
Hôpital Saint-Louis
Paris, France · Withdrawn
CHU de Poitiers - La Miletrie
Poitiers, France · Active not recruiting
CHU Pontchaillou
Rennes, France · Withdrawn
Rambam Medical Center
Haifa, Israel · Active not recruiting
Sourasky Medical Centre
Tel Aviv, Israel · Recruiting
Asst Papa Giovanni Xxiii
Bergamo, Lombardy, Italy · Active not recruiting
A.O. Spedali Civili Di Brescia-P.O. Spedali Civili
Brescia, Lombardy, Italy · Completed
Nagoya City University Hospital
Aichi, Japan · Withdrawn
National Hospital Organization Okayama Medical Center
Okayama, Japan · Withdrawn
The Cancer Institute Hospital of JFCR
Tokyo, Japan · Withdrawn
Yamagata University Hospital
Yamagata, Japan · Active not recruiting
Uniwersyteckie Centrum Kliniczne
Gdansk, Poland · Withdrawn
Pratia Onkologia Katowice
Katowice, Poland · Active not recruiting
Uniwersytecki Szpital Kliniczny w Poznaniu
Późna, Poland · Withdrawn
Seoul National University Hospital
Seoul, South Korea · Recruiting
Samsung Medical Center
Seoul, South Korea · Recruiting
Hospital Universitari Vall d'Hebron
Barcelona, Spain · Recruiting
Hospital General Universitario Gregorio Marañon
Madrid, Spain · Recruiting
University College London Hospitals NHS Foundation Trust
London, United Kingdom · Recruiting
Royal Marsden Hospital
Sutton, United Kingdom · Active not recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.